Sionna Therapeutics, Inc.
SIONHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Sionna Therapeutics, Inc. focuses on Biotechnology services and products. Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). At a $2.23B market cap, Sionna Therapeutics, Inc. ranks as a mid-cap company within healthcare. It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Market Cap
$2.23B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-17.63
EPS (TTM)
$-2.03
EPS (Fwd)
$-2.80
ROE
-26.7%
ROA
-18.3%
Cash
$216.2M
Total Debt
$8.4M
Free CF
-$45.7M
52W Change
195.2%
Annual Financials
Cash vs Debt
Sionna Therapeutics, Inc. holds $216.2M in cash against $8.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$45.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -26.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, SION has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SION.